drugset
drugset / Trial / NCT02345044

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

NCT02345044 ↗

Phase 2 Completed 426 enrolled Daiichi Sankyo
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese hypertensive subjects. Primary endpoint is change from baseline in sitting systolic and diastolic blood pressure.

Timeline

Start
2015-01
Primary completion
2015-08
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CS-3150 Unknown 1.25 mg Oral
Subject CS-3150 Unknown 2.5 mg Oral
Subject CS-3150 Unknown 5 mg Oral
Comparator Eplerenone Unknown 50 mg Oral
Comparator Eplerenone Unknown 100 mg Oral

Indications

essential hypertension